Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
11.07
+0.02 (0.18%)
At close: Sep 16, 2026, 4:00 PM EDT
11.04
-0.03 (-0.27%)
After-hours: Sep 16, 2026, 4:10 PM EDT
Benitec Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
386.15M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | - | - | - |
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | - | - | - |
| Jun 30, 2023 | 75.00K | 2.00K | 2.74% |
| Jun 30, 2022 | 73.00K | 14.00K | 23.73% |
| Jun 30, 2021 | 59.00K | -43.00K | -42.16% |
| Jun 30, 2020 | 102.00K | -12.10M | -99.16% |
| Jun 30, 2019 | 12.20M | 8.81M | 259.85% |
| Jun 30, 2018 | 3.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fennec Pharmaceuticals | 59.22M |
| Editas Medicine | 47.01M |
| vTv Therapeutics | 36.84M |
| Orchestra BioMed Holdings | 31.98M |
| X4 Pharmaceuticals | 15.85M |
| Evommune | 10.00M |
BNTC News
- 1 day ago - Benitec Biopharma price target raised to $17 from $16 at Wedbush - TheFly
- 1 day ago - Benitec Biopharma price target raised to $17 from $16 at Wedbush - TheFly
- 2 days ago - Benitec Biopharma files $200M mixed securities shelf - TheFly
- 2 days ago - Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update - GlobeNewsWire
- 2 days ago - Benitec Biopharma Earnings release: Q4 2026 - Filings
- 2 days ago - Benitec Biopharma Annual report: Q4 2026 - Filings
- 2 days ago - Benitec Biopharma Registration statement: Registration filing - Filings
- 7 weeks ago - Wedbush bullish on Benitec Biopharma, initiates with an Outperform - TheFly